Search the Archives           Subscribe           About this News Service           Reader Comments


Archived updates for Thursday, July 28, 2005

An Incremental Cost-Benefit Analysis of Worldwide Patent Coverage

In "Patent Filing Strategies for Pharmaceutical Products: A Simple Cost-Benefit Analysis Based on Filing Costs and Pharmaceutical Sales," AIPLA QJ (Spring 2005), Robert Silverman, General Counsel at Millenium Pharmaceuticals, looks at what countries should be protected in order to get the most bang for the pharmaceutical patent buck. His analysis starts with a "Return Value Score," or RVS, that divides each country's pharmacetical sales by its patent filing cost. He then divides the 44 countries that he considered into 4 groups depending upon their RVS:
  • Group A - all counries, average RVS=1.6 (99% market coverage, $283,000 filing cost)
  • Group B - all countries with an RVS=10 or greater, RVS=138 (95%, $96,000)
  • Group C - PCT member countries with an RVS=10 or greater, RVS=161 (93%, $81,000)
  • Group D - All countries with an RVS of 20 or greater, RVS=206 (91%, $62,000)

These numbers, along with his estimated PCT national stage filing cost data, result in the following chart showing Percent Market Coverage and PCT National Stage Cost for each Group:

Mr. Silverman draws two conclusions from this chart. First, selecting option B over option D, increases filing costs about 35% in order to gain exclusivity in only about an extra 4% of the world market. Second, the cost of exclusity increases dramatically for anything over about 95% of the world market.

He goes on to explain why reducing translation cost (such as by reducing the number of pages in the speciification) is not likely to matter when the RVS for a particular country is well below a minimum RVS, such as 138 for Group B. However, when the analysis is focussed on just European Patent Convention members, the high translation costs for Sweden, Denmark, Hungary, and Finland, mean that "omission of these four countries might make sense in a European-lite strategy."

Furthermore, since most of the revenue attributable to a European pharmaceutical patent is produced during the period of the so-called "Supplementary Protection Certificate," patents in Denmark, Finland, Slovakia, Latvia, and Estonia can have a negative net present value. However, the NPV calculation can be highly sensitive to certain variables, especially in countries where the NPV is only slightly negative.

Nonetheless, there are still big differences in the patent strategies of pharmaceutical companies. Some companies routinely file patent applications in fifty to seventy countries while others file in over ninety countries.

    (1)comment(s)     translate     More Updates     Send    

1 Comments:

Anonymous Anonymous said...

^^Thanks!!

婚前徵信婚姻感情大陸抓姦外遇抓姦法律諮詢家暴婚前徵信尋人感情挽回大陸抓姦離婚工商徵信婚前徵信外遇抓姦感情挽回尋人大陸抓姦離婚家暴工商徵信法律諮詢跟蹤工商徵信婚前徵信感情挽回外遇抓姦法律諮詢家暴尋人大陸抓姦離婚大陸抓姦外遇尋人家暴工商徵信法律諮詢家暴感情挽回大陸抓姦外遇婚前徵信離婚尋人工商徵信外遇抓姦法律諮詢家暴婚前徵信大陸抓姦尋人感情挽回外遇抓姦婚前徵信感情挽回尋人大陸抓姦工商徵信法律諮詢離婚家暴工商徵信外遇抓姦法律諮詢家暴婚前徵信尋人感情挽回大陸抓姦離婚婚前徵信工商徵信外遇抓姦尋人離婚家暴大陸抓姦感情挽回法律諮詢離婚感情挽回婚前徵信外遇抓姦家暴尋人工商徵信外遇抓姦法律諮詢家暴婚前徵信尋人感情挽回">徵大陸抓姦離婚婚前徵信工商徵信外遇抓姦尋人離婚家暴大陸抓姦感情挽回法律諮詢

April 07, 2009 4:38 AM  

Post a Comment

<< Home